What is ALS Phase II Ibudilast IBU-ALS-1201 Study?

Category: Others

true

Generic name: Ibudilast

This is a Phase II trial comparing the use of a medication known as ibudilast to placebo in 60 patients with ALS. This study is designed to measure the safety, efficacy, and tolerability of ibudilast when added to treatment with riluzole compared to placebo. NCT02238626

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 0
Moderate 0
Mild 1
None 4

Commonly reported side effects and conditions associated with ALS Phase II Ibudilast IBU-ALS-1201 Study

Side effect Patients
Stomach pain 1

Why patients stopped taking ALS Phase II Ibudilast IBU-ALS-1201 Study

Multiple reasons could be selected

Reason Patients
Course of treatment ended 2
See all 2 patients who've stopped taking ALS Phase II Ibudilast IBU-ALS-1201 Study

Duration

Stopped taking ALS Phase II Ibudilast IBU-ALS-1201 Study

Duration Patients
6 months - 1 year 2
Adherence
Adherence Evaluations
Always 5
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 0
A little hard to take 1
Not at all hard to take 4
Cost per month
Cost per month Evaluations
$200+ 0
$100-199 0
$50-99 0
$25-49 0
< $25 2
Not specified 3
Last updated:
There are no evaluations for ALS Phase II Ibudilast IBU-ALS-1201 Study.